title: Maintenance pemetrexed in nonsmall cell lung carcinoma: Outcome analysis from a tertiary care center.
abstract: BACKGROUND
  Maintenance pemetrexed is a standard treatment option for selected non squamous nonsmall cell lung carcinoma patients having a response to platin based doublet. We conducted a clinical audit of such selected patients and report the outcome among the Indian population.
  
  
  OBJECTIVE
  To evaluate the outcomes with maintenance pemetrexed in the patients with locally advanced and metastatic adenocarcinoma lung.
  
  
  OBJECTIVE
  To calculate the progression free survival (PFS), overall survival (OS), and factors affecting the outcome.
  
  
  METHODS
  Data of patients with locally advanced and metastatic adenocarcinoma lung were retrieved from prospectively maintained lung cancer database registered between June 2011 and March 2014. The patients who achieved partial response (n = 87) or stable disease (n = 101) after 6 cycles of pemetrexed platin based doublet and received the maintenance pemetrexed were selected for final analysis (n = 188). Kaplan-Meir survival analysis was used for PFS and OS. Log rank test was used to evaluate the factors affecting the outcome.
  
  
  RESULTS
  Median follow-up is 14 months. The median number of maintenance pemetrexed cycles received is 6 (1-38). Common reason for the discontinuation are disease progression (n = 127), renal toxicity (n = 4), and social/financial (n = 7). Median PFS and OS are 8 months and 20 months, respectively. The patients with baseline pleural effusion had better PFS (9 months vs. 7 months, P = 0.02) and OS (26 months vs. 18 months, P = 0.05). The patients receiving more than 6 cycles of maintenance had improved PFS (12 vs. 7 months, P = 0.002) and OS (26 vs. 16 months, P = 0.05).
  
  
  CONCLUSIONS
  Maintenance pemetrexed is feasible and well tolerated by the majority of Indian patients who achieved the response after platin based doublet. The patients with baseline pleural effusion benefit more with maintenance pemetrexed.
authors.affiliation: Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India.
authors.forename: Avinash Vijaykumar
authors.initials: AV
authors.lastname: Pandey
authors.affiliation: Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India.
authors.forename: Deepa Susan
authors.initials: DS
authors.lastname: Phillip
authors.affiliation: Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India.
authors.forename: Vanita
authors.initials: V
authors.lastname: Noronha
authors.affiliation: Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India.
authors.forename: Amit
authors.initials: A
authors.lastname: Joshi
authors.affiliation: Department of Radiodiagnosis, Tata Memorial Hospital, Mumbai, Maharashtra, India.
authors.forename: Amit
authors.initials: A
authors.lastname: Janu
authors.affiliation: Department of Pathology, Tata Memorial Hospital, Mumbai, Maharashtra, India.
authors.forename: Nirmala
authors.initials: N
authors.lastname: Jambekar
authors.affiliation: Department of Pathology, Tata Memorial Hospital, Mumbai, Maharashtra, India.
authors.forename: Rajesh
authors.initials: R
authors.lastname: Kaushal
authors.affiliation: Department of Radiodiagnosis, Tata Memorial Hospital, Mumbai, Maharashtra, India.
authors.forename: Abhishek
authors.initials: A
authors.lastname: Mahajan
authors.affiliation: Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India.
authors.forename: Kumar
authors.initials: K
authors.lastname: Prabhash
keywords: Effusion; maintenance; pemetrexed
references.citation: Ann Oncol. 2005;16 Suppl 1:i28-9
references.pmid: 15888743
references.citation: J Clin Oncol. 2013 Aug 20;31(24):3004-11
references.pmid: 23835708
references.citation: J Clin Oncol. 2013 Aug 10;31(23):2895-902
references.pmid: 23835707
references.citation: Lancet Oncol. 2012 Mar;13(3):292-9
references.pmid: 22336221
references.citation: J Immunother. 2012 Oct;35(8):629-40
references.pmid: 22996369
references.citation: Indian J Cancer. 2012 Jan-Mar;49(1):74-81
references.pmid: 22842172
references.citation: Eur J Cancer. 2013 Apr;49(6):1205-15
references.pmid: 23477998
references.citation: J Clin Oncol. 2013 Dec 1;31(34):4349-57
references.pmid: 24145346
references.citation: PLoS One. 2013 Apr 19;8(4):e61561
references.pmid: 23620765
references.citation: PLoS One. 2013 Oct 04;8(10):e76164
references.pmid: 24124538
references.citation: Lancet. 2009 Oct 24;374(9699):1432-40
references.pmid: 19767093